MedTrace Logo

Taste Alteration, Sarcopenia, and Malnutrition in Gynecologic Cancer Patients Receiving Carboplatin-Paclitaxel Chemotherapy

NCT07154966 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 102

Last updated 2025-09-04

No results posted yet for this study

Summary

This observational study aims to evaluate chemotherapy-induced taste alterations, sarcopenia, and malnutrition in patients with gynecologic malignancies (ovarian, fallopian tube, and endometrial cancer) treated with standard carboplatin and paclitaxel. Eligible patients will receive six cycles of chemotherapy (carboplatin area under the curve \[AUC\] 5 + paclitaxel 175-200 mg/m², every 21 days), and assessments will be performed at baseline (before chemotherapy), after the 3rd cycle (\~9 weeks), and after the 6th cycle (\~18 weeks). Validated tools will be used, including the Chemotherapy-Induced Taste Alteration Scale (CITAS, Turkish validated, range 18-90; higher scores indicate greater severity of dysgeusia), the Patient-Generated Subjective Global Assessment (PG-SGA, Turkish validated, range 0-35; higher scores indicate worse nutritional status), and Computed Tomography (CT)-based Skeletal Muscle Index (SMI) at the L3 vertebra level.

Conditions

  • Ovarian Cancer (OvCa)
  • Fallopian Tube Cancers
  • Endometrial Cancer
  • Chemotherapy-Induced Taste Alteration
  • Cancer-Associated Malnutrition
  • Cancer-Associated Sarcopeni

Interventions

OTHER

Standard Chemotherapy (Carboplatin-Paclitaxel)

Standard-of-care chemotherapy with carboplatin (AUC 5, every 21 days) and paclitaxel (175-200 mg/m², every 21 days) for six cycles. No additional drugs, dose modifications, or alternative regimens introduced.

Sponsors & Collaborators

  • Ankara Etlik City Hospital

    lead OTHER_GOV

Principal Investigators

  • Galip Can Uyar, MD · Ankara Etlik City Hospital Medical Oncology Department

  • Osman Sütcüoğlu, MD · Gazi University Medical Oncology Department, Ankara

  • Ömür Berna Öksüzoğlu, MD · Ankara Etlik City Hospital Medical Oncology Department

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-03-15
Primary Completion
2025-01-10
Completion
2025-07-01

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07154966 on ClinicalTrials.gov